Table 2 Flagged cases for each syndrome from Whitehorse General Hospital ED-Tracker records, Oct. 1, 2018 – Apr. 30, 2019
Flagged visits by separate fields | Flagged visits by combined fields | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Field | # Hits | PPV (CI) | # Hits | PPV (CI) | Field(s) | # Hits | PPV (CI) | # Hits | PPV (CI) |
Gastrointestinal | Gastrointestinal | ||||||||
Pre-validation | Post-Validation | Pre-validation | Post-Validation | ||||||
CN | 1579 | 0.23 (0.18–0.27) | 746 | 0.44 (0.38–0.49) | CN | 1579 | 0.23 (0.18–0.27) | 746 | 0.44 (0.38–0.49) |
CC | 866 | 0.35 (0.30–0.40) | 295 | 0.40 (0.31–0.48) | CN/CC | 1644 | 0.22 (0.18–0.26) | 759 | 0.45 (0.39–0.50) |
DD | 485 | 0.51 (0.45–0.57) | 236 | 0.87 (0.82–0.91) | CN/CC/DD | 601 | 0.49 (0.43–0.54) | 316 | 0.79 (0.74–0.84) |
Respiratory | Respiratory | ||||||||
Pre-validation | Post-Validation | Pre-validation | Post-Validation | ||||||
CN | 639 | 0.75 (0.71–0.78) | 625 | 0.75 (0.71–0.78) | CN | 639 | 0.75 (0.71–0.78) | 625 | 0.75 (0.71–0.78) |
CC | 19 | 0.21 (0–0.59) | 19 | 0.21 (−0.19–0.59) | CN/CC | 662 | 0.74 (0.70–0.77) | 647 | 0.74 (0.70–0.77) |
DD | 76 | 0.92 (0.86–0.98) | 76 | 0.92 (0.86–0.98) | CN/CC/DD | 548 | 0.84 (0.81–0.87) | 542 | 0.84 (0.81–0.87) |
ILI | ILI | ||||||||
Pre-validation | Post-Validation | Pre-validation | Post-Validation | ||||||
CN | 361 | 0.86 (0.82–0.90) | 356 | 0.87 (0.83–0.91) | CN | 361 | 0.86 (0.82–0.90) | 356 | 0.87 (0.83–0.91) |
CC | 0 | – | 0 | – | CN/CC | 380 | 0.85 (0.81–0.89) | 375 | 0.86 (0.82–0.90) |
DD | 141 | 0.96 (0.92–0.99) | 141 | 0.96 (0.92–0.99) | CN/CC/DD | 482 | 0.87 (0.84–0.90) | 477 | 0.88 (0.85–0.91) |
Rash | Rash | ||||||||
Pre-validation | Post-Validation | Pre-validation | Post-Validation | ||||||
CN | 9 | 0.56 0.12–0.97) | 9 | 0.56 (0.12–0.97) | CN | 9 | 0.56 (0.12–0.97) | 5 | 0.56 (0.12–0.97) |
CC | 0 | – | 0 | 0 (0) | CN/CC | 56 | 0.57 (0.40–0.73) | 56 | 0.57 (0.40–0.73) |
DD | 10 | 0.90 (0.70–1.00) | 10 | 0.90 (0.70–1.09) | CN/CC/DD | 64 | 0.63 (0.47–0.77) | 64 | 0.63 (0.47–0.77) |
Neurological | Neurological | ||||||||
Pre-validation | Post-Validation | Pre-validation | Post-Validation | ||||||
CN | 201 | 0.35 (0.24–0.45) | 193 | 0.35 (0.24–0.46) | CN | 201 | 0.35 (0.24–0.45) | 193 | 0.35 (0.24–0.46) |
CC | 0 | – | 0 | – | CN/CC | 167 | 0.54 (0.44–0.64) | 160 | 0.56 (0.45–0.65) |
DD | 2 | 1.00 (1.00–1.00) | 2 | 1.00 (1.00–1.00) | CN/CC/DD | 6 | 0.83 (0.51–1.00) | 19 | 0.89 (0.75–1.03) |
Mumps | Mumps | ||||||||
Pre-validation | Post-Validation | Pre-validation | Post-Validation | ||||||
CN | 43 | 0.37 (0.14–0.60) | 40 | 0.40 (0.16–0.63) | CN | 43 | 0.37 (0.14–0.60) | 40 | 0.40 (0.16–0.63) |
DD | 17 | 0.94 (0.83–1.00) | 17 | 0.94 (0.83–1.05) | CN/DD | 57 | 0.51 (0.33–0.68) | 17 | 0.94 (0.83–1.05) |